Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allen W Nyhuis

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
CNS Neuroscience & Therapeutics|August 2, 2016
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity DisorderDavid B Clemow, Allen W Nyhuis, Rebecca L Robinson
Cost Effectiveness and Resource Allocation : C/E|May 29, 2009
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleDouglas E Faries, Allen W Nyhuis, Haya Ascher-Svanum
Current Medical Research and Opinion|April 10, 2008
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
Disease Management : DM|October 11, 2005
Outcomes of American Lung Association-Indiana Lung Centers asthma programKent H Summers, Alan J Zillich, Allen W Nyhuis, et al.
BMC Psychiatry|September 4, 2009
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
Journal of Managed Care & Specialty Pharmacy|July 26, 2018
Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific CostsJanet H Ford, Krista Schroeder, Allen W Nyhuis, et al.
BMC Psychiatry|January 30, 2010
Involvement in the US criminal justice system and cost implications for persons treated for schizophreniaHaya Ascher-Svanum, Allen W Nyhuis, Douglas E Faries, et al.
Journal of Managed Care & Specialty Pharmacy|August 30, 2018
Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims DataCasey K Choong, Janet H Ford, Allen W Nyhuis, et al.
BMC Psychiatry|October 6, 2010
Predictors of switching antipsychotic medications in the treatment of schizophreniaAllen W Nyhuis, Douglas E Faries, Haya Ascher-Svanum, et al.
Headache|August 15, 2018
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With GalcanezumabDavid W Ayer, Vladimir Skljarevski, Janet H Ford, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
CNS Neuroscience & Therapeutics|August 2, 2016
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity DisorderDavid B Clemow, Allen W Nyhuis, Rebecca L Robinson
Cost Effectiveness and Resource Allocation : C/E|May 29, 2009
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleDouglas E Faries, Allen W Nyhuis, Haya Ascher-Svanum
Current Medical Research and Opinion|April 10, 2008
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
Disease Management : DM|October 11, 2005
Outcomes of American Lung Association-Indiana Lung Centers asthma programKent H Summers, Alan J Zillich, Allen W Nyhuis, et al.
BMC Psychiatry|September 4, 2009
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
Journal of Managed Care & Specialty Pharmacy|July 26, 2018
Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific CostsJanet H Ford, Krista Schroeder, Allen W Nyhuis, et al.
BMC Psychiatry|January 30, 2010
Involvement in the US criminal justice system and cost implications for persons treated for schizophreniaHaya Ascher-Svanum, Allen W Nyhuis, Douglas E Faries, et al.
Journal of Managed Care & Specialty Pharmacy|August 30, 2018
Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims DataCasey K Choong, Janet H Ford, Allen W Nyhuis, et al.
BMC Psychiatry|October 6, 2010
Predictors of switching antipsychotic medications in the treatment of schizophreniaAllen W Nyhuis, Douglas E Faries, Haya Ascher-Svanum, et al.
Headache|August 15, 2018
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With GalcanezumabDavid W Ayer, Vladimir Skljarevski, Janet H Ford, et al.
Pageof 2